Status:
COMPLETED
Velcade in MALT Lymphoma Patients
Lead Sponsor:
Medical University of Vienna
Conditions:
MALT Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Bortezomib for treatment of disseminated MALT lymphoma or at relapse following HP -eradication,or chemotherapy or radiation.
Detailed Description
The objectives of this study are to evaluate the effectivity and the safety of bortezomib in patients with disseminated MALT lymphoma or at relapse following HP-eradication, or chemotherapy or radiati...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- patients with histologically confirmed MALT lymphoma with measurable disease (stage I-IV)
- with first or greater relapse after HP-eradication, radiation or chemotherapy ,
- age \> 18 years
- must be able to tolerate therapy and have adequate cardiac, renal and hepatic function
- ECOG status of \<\_ 2
- must be capable of understanding the purpose of the study and given written informed consent
Exclusion
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00373906
Last Update
November 27 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.